Sio Gene Therapies, Inc. (SIOX): Price and Financial Metrics
GET POWR RATINGS... FREE!
SIOX Stock Price Chart Interactive Chart >
SIOX Price/Volume Stats
| Current price | $0.36 | 52-week high | $2.95 |
| Prev. close | $0.33 | 52-week low | $0.23 |
| Day low | $0.34 | Volume | 554,900 |
| Day high | $0.38 | Avg. volume | 694,792 |
| 50-day MA | $0.37 | Dividend yield | N/A |
| 200-day MA | $1.12 | Market Cap | 26.51M |
Sio Gene Therapies, Inc. (SIOX) Company Bio
Sio Gene Therapies, Inc. operates as a clinical-stage biopharmaceutical company. The Company develops gene therapies that transform the treatment of serious neurodegenerative diseases. Sio Gene Therapies serves customers worldwide.
Latest SIOX News From Around the Web
Below are the latest news stories about Sio Gene Therapies Inc that investors may wish to consider to help them evaluate SIOX as an investment opportunity.
Insiders who bought stock earlier this year lose -US$183k as Sio Gene Therapies Inc. (NASDAQ:SIOX) drops to US$48mThe recent 10% drop in Sio Gene Therapies Inc.'s ( NASDAQ:SIOX ) stock could come as a blow to insiders who purchased... |
Sio Gene Therapies (SIOX) Gets a Hold Rating from Leerink PartnersIn a report issued on February 11, Mani Foroohar from Leerink Partners maintained a Hold rating on Sio Gene Therapies (SIOX – Research Report), with a price target of $1.00. The company's shares closed last Tuesday at $0.69, close to its 52-week low of $0.66. According to TipRanks.com, Foroohar is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -18.0% and a 38.3% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Recursion Pharmaceuticals, and 4D Molecular Therapeutics. |
H.C. Wainwright Keeps Their Buy Rating on Sio Gene Therapies (SIOX)H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Sio Gene Therapies (SIOX – Research Report) today and set a price target of $7.00. The company's shares closed last Thursday at $0.80, close to its 52-week low of $0.75. According to TipRanks.com, Pantginis has 0 stars on 0-5 stars ranking scale with an average return of -14.3% and a 28.0% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals. Sio Gene Therapies has an analyst consensus of Strong Buy, with a price target consensus of $5.00, representing a 525.0% upside. |
Sio Gene Therapies GAAP EPS of -$0.35 misses by $0.12Sio Gene Therapies press release (SIOX): Q3 GAAP EPS of -$0.35 misses by $0.12.Cash and cash equivalents of $81.9M as of December 31, 2021 Shares -2.50% PM. |
Sio Gene Therapies Announces Corporate Updates and Fiscal Third Quarter 2021 Financial ResultsCompany prioritizing industry-leading clinical-stage programs, AXO-AAV-GM1 and AXO-AAV-GM2, the first potential disease-modifying therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff disease$81.9 million of cash and cash equivalents as of December 31, 2021, providing expected cash runway into calendar H2 2023 beyond the expected dates of major upcoming milestones for the AXO-AAV-GM1 and AXO-AAV-GM2 gene therapy programs NEW YORK and DURHAM, N.C., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Sio Gene The |
SIOX Price Returns
| 1-mo | 14.32% |
| 3-mo | -46.78% |
| 6-mo | -72.52% |
| 1-year | -87.32% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -72.09% |
| 2021 | -53.60% |
| 2020 | -45.70% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...